Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Lunella Biotech Inc. is navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and 3 distinct art units. This distribution indicates that multiple examiners are likely operating within the same specialized group, which may lead to some consistency in procedural expectations across the portfolio.
JEAN-LOUIS, SAMIRA JM is the busiest examiner for the company. This examiner is currently responsible for 1 pending office action. Since there are 4 distinct examiners for the 4 pending office actions, the workload is evenly distributed. This lack of examiner-level consolidation requires the company to manage four separate examiner relationships simultaneously.
The presence of 3 distinct art units for 4 pending office actions suggests a focused technical scope within the Biotechnology & Pharmaceuticals sector. However, the use of 4 distinct examiners means that practitioners must still account for individual variations in examination style. The 1 pending office action assigned to JEAN-LOUIS, SAMIRA JM represents the typical workload per examiner for the company's current applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JEAN-LOUIS, SAMIRA JM | 1 | 61.0% | +45.2% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642935 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | VALENROD, YEVGENY | 10d overdue |
| 18722474 | MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS | JEAN-LOUIS, SAMIRA JM | — |
| 17642935 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | AEDER, SEAN E | — |
| 17414842 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | MACH, ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1642 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722474 | MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS | JEAN-LOUIS, SAMIRA JM | — | §112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | VALENROD, YEVGENY | 1628 | §112 | Final Rejection | 10d overdue | Pending | Dec 15, 2023 |
| 17642935 | ATP-BASED CELL SORTING AND HYPERPROLIFERATIVE CANCER STEM CELLS | AEDER, SEAN E | 1642 | §102§112 | Non-Final OA | — | Pending | Mar 14, 2022 |
| 17414842 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | MACH, ANDRE | 1615 | §103 | Non-Final OA | — | Pending | Jun 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial